A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HR Positive HER2 Negative Advanced Breast Cancer
Interventions: DRUG: Chidamide
Sponsor: Tianjin Medical University Cancer Institute and Hospital